Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET
JR Tseng, KW Kang, M Dandekar… - Journal of Nuclear …, 2008 - Soc Nuclear Med
The purpose of this study was to evaluate the efficacy of CE-355621, a novel antibody
against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small …
against c-Met, in a subcutaneous U87 MG xenograft mouse model using 18F-FDG small …
Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor …
EM Kim, EH Park, SJ Cheong, CM Lee, DW Kim… - Nuclear medicine and …, 2009 - Elsevier
c-Met is a receptor tyrosine kinase involved in tumor cell growth, invasion, metastases and
angiogenesis. Overexpression of c-Met is frequently observed in several tumor types. Here …
angiogenesis. Overexpression of c-Met is frequently observed in several tumor types. Here …
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
F Kraeber-Bodéré, T Carlier… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Two mitogen-activated protein kinase kinase (MAPK2, also known as MEK) inhibitors were
assessed with 18F-FDG PET in separate phase I clinical studies, clearly illustrating the …
assessed with 18F-FDG PET in separate phase I clinical studies, clearly illustrating the …
Differential 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models
C Cullinane, DS Dorow, S Jackson… - Journal of Nuclear …, 2011 - Soc Nuclear Med
The ability of PET to image functional changes in tumors is increasingly being used to
evaluate response and predict clinical benefit to conventional and novel cancer therapies …
evaluate response and predict clinical benefit to conventional and novel cancer therapies …
[HTML][HTML] Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts
W Li, H Zheng, J Xu, S Cao, X Xu, P Xiao - PloS one, 2018 - journals.plos.org
Objectives c-Met is a receptor tyrosine kinase shown inappropriate expression and actively
involved in progression and metastasis in most types of human cancer. Development of c …
involved in progression and metastasis in most types of human cancer. Development of c …
[HTML][HTML] 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics
M Pool, AGT Terwisscha van Scheltinga, A Kol… - European Journal of …, 2017 - Springer
Purpose c-MET and its ligand hepatocyte growth factor are often dysregulated in human
cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or …
cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy or …
Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing …
PURPOSE: c-Met is overexpressed in some non-small cell lung cancer (NSCLC) cell lines
and tissues. Cell lines with higher levels of c-Met expression and phosphorylation depend …
and tissues. Cell lines with higher levels of c-Met expression and phosphorylation depend …
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30
LR Perk, M Stigter-van Walsum, GWM Visser… - European journal of …, 2008 - Springer
Abstract Purpose Targeting the c-Met receptor with monoclonal antibodies (MAbs) is an
appealing approach for cancer diagnosis and treatment because this receptor plays a …
appealing approach for cancer diagnosis and treatment because this receptor plays a …
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET
HJWL Aerts, L Dubois, L Perk… - Journal of Nuclear …, 2009 - Soc Nuclear Med
The epidermal growth factor receptor (EGFR) is highly expressed in a significant number of
human malignancies, and its expression is associated with tumor aggressiveness and …
human malignancies, and its expression is associated with tumor aggressiveness and …
A novel antagonist anti‐cMet antibody with antitumor activities targeting both ligand‐dependent and ligand‐independent c‐Met receptors
A Gonzalez, M Broussas, C Beau‐Larvor… - … journal of cancer, 2016 - Wiley Online Library
c‐Met is a prototypic member of a sub‐family of RTKs. Inappropriate c‐Met activation plays a
crucial role in tumor formation, proliferation and metastasis. Using a key c‐Met dimerization …
crucial role in tumor formation, proliferation and metastasis. Using a key c‐Met dimerization …